Lenvatinib Plus Chemotherapy for pNET Liver Metastases
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This prospective, non-randomized, concurrent parallel-controlled study will evaluate treatment response and resistance mechanisms in patients with pancreatic neuroendocrine tumors with liver metastases (pNET-LM) receiving second-line systemic therapy after failure of first-line treatment. Eligible patients will receive either lenvatinib combined with chemotherapy or chemotherapy alone according to the study protocol and clinical treatment strategy. The clinical efficacy and safety of the two treatment strategies will be evaluated using objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events. Peripheral blood samples will be collected before treatment, during early treatment, and at disease progression. Circulating cell-free DNA (cfDNA) and peripheral blood mononuclear cells (PBMCs) will be analyzed to investigate molecular and immune changes associated with treatment response, primary resistance, and acquired resistance. The study aims to identify potential biomarkers for predicting treatment response and to improve understanding of resistance mechanisms in pNET-LM.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzony histologicznie lub cytologicznie nowotwór neuroendokrynny trzustki
- •Przerzuty do wątroby potwierdzone badaniem obrazowym
- •Progresja choroby po pierwszym leczeniu i kwalifikacja do drugiej linii terapii
- •Co najmniej jeden mierzalny guz
- •Dobry stan ogólny (ECOG 0-1)
- •Prawidłowe funkcje wątroby, nerek i krwi
- •Oczekiwana długość życia co najmniej 12 tygodni
✗ Disqualifies
- •Wysoko zaawansowany nowotwór neuroendokrynny lub pochodzący spoza trzustki
- •Wcześniejsze leczenie lenvatinibem
- •Niekontrolowana choroba serca lub wysokie ciśnienie krwi
- •Aktywna ciężka infekcja lub inne niekontrolowane poważne choroby
- •Przerzuty do mózgu powodujące objawy
- •Ciąża lub karmienie piersią
- •Udział w innym badaniu klinicznym mogącym wpłynąć na wyniki
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Chinese Academy of Medical Sciences，Peking Union Medical College Hospital
Beijing, China
Trial contact
Jiayue Li
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.